Opthea Ltd
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing novel therapies to treat highly prevalent and progressive retinal eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s lead product candidate OPT-302 is in pivotal Phase III clinical trials and being developed for use in combination with anti- Vascular Endothelial Growth Factor (VEGF-A) monotherapies to achieve broader inhibition of the VEGF family. OPT-302 has the potential to address the unmet medical need of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. The Company is advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.